- Home
- CLPT vs CLLS Comparison
CLPT vs CLLS Comparison
Compare CLPT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | CLLS |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.5M | 394.4M |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CLPT | CLLS |
|---|---|---|
| Price | $13.26 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $8.33 |
| AVG Volume (30 Days) | ★ 545.4K | 32.4K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | N/A |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $1.35 |
| 52 Week High | $30.10 | $5.48 |
Technical Indicators
Market Signals| Indicator | CLPT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 37.61 |
| Support Level | $12.87 | $3.05 |
| Resistance Level | $13.59 | $3.83 |
| Average True Range (ATR) | 1.02 | 0.17 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 48.45 | 24.19 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.